date:Jul 17, 2012
The firm, which is expanding its facility in Sherbrooke, Qubec, to meet growing demand, said nutraceutical sales rose 43% to $6.14m in the three months to May 31, while net profits in the division were $48,000, compared with a net loss of $70,000 for the same period last year.
Consolidated revenues - which include figures from the Acasti Pharma and NeuroBiopharm businesses were up 44% to $6.153m while net losses were $1.695m compared with a $1.258m net loss for Q1 2012.
Chief financial office